Publications by authors named "Muhammad Baluom"

Claim this Profile
E
Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies.
Paul Martin, Michael Gillen, David Millson, Stuart Oliver, Clive Brealey, Muhammad Baluom

Drugs R D· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies.
Paul Martin, Michael Gillen, David Millson, Stuart Oliver, Clive Brealey, Muhammad Baluom

Clin Ther· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies.
Muhammad Baluom, Elliott B Grossbard, Tim Mant, David T W Lau

Br J Clin Pharmacol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Significant reduction of acute cardiac allograft rejection by selective janus kinase-1/3 inhibition using R507 and R545.
Tobias Deuse, Xiaoqin Hua, Vanessa Taylor, Mandy Stubbendorff, Muhammad Baluom

Transplantation· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis.
Muhammad Baluom, Emil Samara, Elliott B Grossbard, David T-W Lau

J Clin Pharmacol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation.
David J Sweeny, Weiqun Li, Jeffrey Clough, Somasekhar Bhamidipati, Rajinder Singh, Muhammad Baluom

Drug Metab Dispos· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen.
John McLaughlin, Vadim Markovtsov, Hui Li, Steve Wong, Marina Gelman, Muhammad Baluom

J Cancer Res Clin Oncol· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing.
George R Clemens, Raymond E Schroeder, Steven H Magness, Elizabeth V Weaver, Joseph W Lech, Muhammad Baluom

Birth Defects Res A Clin Mol Teratol· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus.
Frances Rena Bahjat, Polly R Pine, Andrea Reitsma, Gail Cassafer, Muhammad Baluom

Arthritis Rheum· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
Sylvia Braselmann, Vanessa Taylor, Haoran Zhao, Su Wang, Catherine Sylvain, Muhammad Baluom

J Pharmacol Exp Ther· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients.
Lynda Frassetto, Muhammad Baluom, Wolfgang Jacobsen, Uwe Christians, Michelle E Roland

Transplantation· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of soluble complement receptor type 1 on acute humoral xenograft rejection in hDAF-transgenic pig-to-primate life-supporting kidney xenografts.
Tuan T Lam, Bernard Hausen, Laurie Hook, Macy Lau, John Higgins, Muhammad Baluom

Xenotransplantation· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Automated, fast, and sensitive quantification of drugs in human plasma by LC/LC-MS: quantification of 6 protease inhibitors and 3 nonnucleoside transcriptase inhibitors.
Wolfgang Egge-Jacobsen, Matthias Unger, Claus U Niemann, Muhammad Baluom, Sumiko Hirai

Ther Drug Monit· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel percutaneous adventitial drug delivery system for regional vascular treatment.
Fumiaki Ikeno, Jennifer Lyons, Hideaki Kaneda, Muhammad Baluom, Leslie Z Benet

Catheter Cardiovasc Interv· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis